Plasma ribavirin trough concentrations at week 4 predict hepatitis C virus (HCV) relapse in HIV-HCV-coinfected patients treated for chronic hepatitis C.

Antimicrobial Agents and Chemotherapy
Judit MorelloSonia Rodríguez-Novoa

Abstract

The influence of ribavirin trough concentrations (RBV C(trough)) on the risk of hepatitis C virus (HCV) relapse was retrospectively analyzed in 99 HIV-HCV-coinfected patients who achieved end-of-treatment response with pegylated alpha interferon plus weight-based RBV. The independent predictors (odds ratio [OR] [95% confidence interval (CI)]) of HCV relapse were RBV plasma C(trough) of <2.5 microg/ml (4.5 [1.3 to 15.5]), baseline serum HCV RNA (2.5 [1.2 to 5.1]), and HCV genotype 1 or 4 (13.3 [2.6 to 66.7]). Monitoring of RBV C(trough) may permit early adjustment of RBV dosage to avoid HCV relapse.

References

Sep 27, 2002·The New England Journal of Medicine·Michael W FriedJian Yu
May 26, 2004·AIDS Research and Human Retroviruses·Vincent SorianoJuan González-Lahoz
Jul 30, 2004·The New England Journal of Medicine·Francesca J TorrianiUNKNOWN APRICOT Study Group
Jul 30, 2004·The New England Journal of Medicine·Raymond T ChungUNKNOWN AIDS Clinical Trials Group A5071 Study Team
Dec 16, 2004·JAMA : the Journal of the American Medical Association·Fabrice CarratUNKNOWN ANRS HCO2 RIBAVIC Study Team
Jul 13, 2005·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Ana Lucía RendónVincent Soriano
Aug 19, 2005·Nature·Jordan J Feld, Jay H Hoofnagle
Nov 5, 2005·The Journal of Infection·Esther VoigtUNKNOWN Kaad Study Group
Apr 27, 2007·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Firouzé Bani-SadrUNKNOWN Agence Nationale pour la Recherche contre le SIDA et les Hépatites Virales HC02-Ribavic Study Team
Dec 12, 2007·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Alessandra MangiaAngelo Andriulli
Jan 4, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Fred PoordadPaul Martin
Oct 22, 2008·The Journal of Antimicrobial Chemotherapy·Judit MorelloVincent Soriano
May 1, 2009·The New England Journal of Medicine·Christophe HézodeUNKNOWN PROVE2 Study Team

❮ Previous
Next ❯

Citations

Apr 25, 2012·The Canadian Journal of Hospital Pharmacy·Alice TsengDeborah Yoong
Aug 23, 2011·Expert Opinion on Investigational Drugs·Paulina Deming, Sanjeev Arora
Aug 16, 2011·Revista clínica española·M E Valencia, V Moreno
Aug 9, 2011·Thérapie·Caroline SolasUNKNOWN Groupe Suivi Therapeutique Pharmacologique de la Societe Francaise de Pharmacologie et de Therapeutique
May 21, 2011·Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver·Véronique Loustaud-RattiUNKNOWN OPTIRIB group
Aug 15, 2013·Therapeutic Drug Monitoring·Sandra BodeauEtienne Brochot
Nov 23, 2011·Journal of Clinical Gastroenterology·Paloma Muñoz-de-RuedaJavier Salmerón

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.